September 16, 2026, (Inside AI) — Novo Nordisk has partnered with Anthropic to integrate Claude models into its drug discovery and development pipeline, the companies said Wednesday. The Danish pharmaceutical giant will use Anthropic's AI to accelerate the identification of new medicines, a process that traditionally takes years and billions of dollars.
The deal marks one of the most significant moves by a major drugmaker into generative AI, signaling a shift in how pharmaceutical companies approach early-stage research. Novo Nordisk, known for its blockbuster diabetes and obesity drugs, is betting that large language models can cut through the complexity of biological data.
Anthropic's Claude models, which compete with OpenAI's GPT series, have gained traction in regulated industries for their safety features and ability to handle long documents. Novo Nordisk plans to deploy Claude across multiple stages of drug development, from target identification to clinical trial design. The companies did not disclose financial terms or the duration of the partnership.
"We are always looking for ways to bring new treatments to patients faster," said a Novo Nordisk spokesperson. "This collaboration with Anthropic is part of our broader effort to leverage AI across our research and development."
Read: ByteDance Spins Off Anew Labs, Raises $290M for AI Drug Discovery
The partnership comes as pharmaceutical firms face mounting pressure to improve R&D efficiency. On average, bringing a new drug to market costs over $2 billion and takes more than a decade, according to industry estimates. Many candidates fail in late-stage trials, wasting years of work. AI promises to reduce that waste by predicting which molecules are likely to succeed.
Anthropic has been courting life sciences companies as part of its enterprise strategy. In recent months, the company has highlighted Claude's ability to parse scientific literature, generate hypotheses, and assist with regulatory submissions. The Novo Nordisk deal adds a marquee name to its client list.
"We believe AI can be a powerful tool for scientific discovery," said an Anthropic spokesperson. "Working with Novo Nordisk allows us to apply Claude to some of the most challenging problems in medicine."
Novo Nordisk's move follows similar efforts by rivals. Sanofi has partnered with OpenAI and Formation Bio, while AstraZeneca uses AI for drug repurposing. The trend reflects a broader recognition that AI can augment human researchers, not replace them.
Analysts caution that AI's impact on drug development remains unproven at scale. While AI has shown promise in identifying novel targets and designing molecules, few AI-discovered drugs have reached late-stage trials. The Novo Nordisk-Anthropic partnership will be watched as a test case.
"The real question is whether AI can improve success rates in clinical trials," said an industry analyst who spoke on condition of anonymity. "That's where the biggest costs lie, and that's where we need to see results."
Read: Anthropic Launches Claude for Financial Services, Challenging OpenAI in Finance AI
Novo Nordisk has invested heavily in AI in recent years, building internal teams and acquiring startups. The company's research focus includes metabolic diseases, cardiovascular conditions, and rare blood disorders. Using Claude, Novo Nordisk aims to mine vast datasets of genetic and clinical information to find new drug targets.
Anthropic, meanwhile, continues to expand its presence in healthcare. The company has emphasized safety and interpretability, which resonate with pharmaceutical companies wary of AI hallucinations. Claude's ability to cite sources and avoid fabricating information is a key selling point.
The partnership also highlights the growing convergence of AI and biotech. As AI models become more capable, they are moving from general-purpose tools to specialized assistants for scientists. Novo Nordisk and Anthropic will likely develop custom applications of Claude tailored to drug discovery workflows.
Financial details were not disclosed, but such partnerships often involve multi-year commitments and significant licensing fees. Novo Nordisk's stock rose slightly on the news, while Anthropic remains private.
The collaboration is expected to begin immediately, with initial projects focused on target discovery and preclinical research. If successful, it could pave the way for broader adoption of AI across Novo Nordisk's pipeline. The companies plan to share updates as the partnership progresses.
For now, the deal underscores a simple fact: AI has moved from the margins of drug development to the center. Novo Nordisk and Anthropic are betting that together, they can shorten the long road from lab to patient.
